Agensys, Inc.,?founded by oncologists at UCLA,?began operations in Santa Monica in 1997. In 2007, Astellas Pharma Inc. acquired Agensys with the plan to make it the center of the company’s antibody product discovery and development operations.?Today, the company specializes in therapeutic antibody research and development in cancer. Agensys is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers.

The MAb product pipeline is being generated to Agensys’ diverse portfolio of proprietary, clinically relevant cancer targets that encompass 14 types of solid tumors. Agensys’ target portfolio and related products are protected by 119 issued/33 allowed patents and over 300 applications. The company has full capabilities to generate, develop and manufacture antibody products.

Agensys is progressing a pipeline of both naked and antibody-drug conjugated (ADC) therapeutic antibodies, directed at a variety of cancer indications, including those of the prostate, kidney, pancreas, ovary, bladder, lung, colon, breast and skin. ADC products are based on toxin platform technologies developed by Seattle Genetics.

Agensys has a rich pipeline that includes four monoclonal antibody products in clinical trials:

  1. AGS-1C4D4, directed to Prostate Stem Cell Antigen (PSCA), a novel target for prostate, pancreatic, and bladder cancers (NCT01608711,?NCT00519233,?NCT00902291)
  2. AGS-5ME, Agensys’ first ADC, directed to AGS-5, a novel target in multiple epithelial tumors, co-developed with Seattle Genetics;
  3. AGS-16M8F, an ADC developed for the treatment of metastatic renal cancer (NCT01114230); and
  4. AGS-22M6E, an ADC developed for multiple solid tumors to include breast, bladder, lung, and pancreatic cancers (NCT01409135)

Agensys’ pre-clinical pipeline encompasses over 10 different MAb programs.

Advertisement #3

2225 Colorado Ave.
Santa Monica, CA 90404

Web: Agensys

Advertisement #5